This move is archived. Current quotes and coverage live on the stock page.
Get MSCL alerts:
Satellos Bioscience Inc. is on the rise, reflecting positive investor sentiment and potential growth prospects.
Satellos Bioscience Inc. (MSCL.TO) is gaining today, with shares up by 1.76% to close at CA$13.84. This upward movement comes as investors react positively to the company's ongoing developments and strategic initiatives.
Investor takeaway: With a market cap of approximately CA$278.7 million, Satellos's recent performance highlights its potential as a promising investment in the biotech sector, especially with its focus on innovative treatments.
Advertisement
Satellos Bioscience Inc.
MSCL.TO
MSCL.TO
Satellos Bioscience Inc.
WealthAwesomeMarket cap
$275.81M
52W high
$18.98
52W low
$7.32
1W change
-6.14%
Beta
1.14
Analyst Price Targets
Based on analyst covering MSCL ยท as of Sep 17, 2026
Wall Street analysts forecast MSCL stock price to rise 35.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$17.67
+35.9% Upside
Current Price
C$13.00
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MSCL's historical volatility
30-Day Vol
51.6%
Annualized
90-Day Vol
71.1%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$15.58
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$13.83 | C$11.57 โ C$16.53 |
| 60 trading days | C$14.68 | C$11.41 โ C$18.88 |
| 90 trading days | C$15.58 | C$11.44 โ C$21.21 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Satellos's market cap reaches CA$278.7 million
With a market cap nearing CA$279 million, Satellos is gaining traction among investors, reflecting confidence in its clinical development pipeline and financial stability.
Bull case
The company has made significant strides recently, including activating clinical trial sites and maintaining a strong cash position. These factors suggest that Satellos is well-prepared for future growth. Plus, a potential Nasdaq listing could draw in more institutional investors.
Bear case
Despite today's gains, Satellos currently has no profit margin and operates in a competitive biotech landscape. This situation could pose risks if clinical trials donโt meet expectations or if funding becomes a concern.
Advertisement
Recent Developments Fueling Investor Interest
Satellos's recent activation of clinical trial sites in its BASECAMP study and the start of the TRAILHEAD study in the U.S. have sparked investor enthusiasm. The company reported a cash position of CA$69.9 million, providing a solid financial runway through 2027, which is crucial for sustaining its development efforts.
Market Reactions and Future Outlook
The stock's performance today reflects a broader positive sentiment in the biotech sector, particularly as companies like Satellos continue to innovate. Investors are keenly watching for updates regarding the potential Nasdaq listing, which could significantly enhance liquidity and attract new capital.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
